Literature DB >> 2011407

[Evaluation of ciprofloxacin versus amoxicillin + clavulanic acid or erythromycin for the empiric treatment of community-acquired pneumonia].

Y Mouton1, C Beuscart, O Leroy, F Ajana, J Charrel.   

Abstract

For the empiric management of community-acquired pneumonia, ciprofloxacin (750 mg b.i.d.) was compared with two antibiotics frequently used in this indication, i.e., amoxicillin + clavulanic acid and erythromycin. One hundred and forty-two patients were randomized in this prospective study. Among them, the 63 patients with bacteriologically documented disease were evaluated. Clinical recovery was achieved in 73.3% of patients in the ciprofloxacin group (22/30) versus 81.8% of patients in the amoxicillin + clavulanic acid or erythromycin group (27/33) (non-significant difference). Clinical failures seen with ciprofloxacin were found to be correlated with recovery of Streptococcus pneumoniae. Ciprofloxacin is effective in pneumonia but should be used only in cases where Streptococcus pneumoniae can be excluded as the causative agent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2011407

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  3 in total

Review 1.  Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

Authors:  Noa Eliakim-Raz; Eyal Robenshtok; Daphna Shefet; Anat Gafter-Gvili; Liat Vidal; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

Review 2.  Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.

Authors:  C Chidiac; Y Mouton
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 3.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.